**POSTPONED**

Due to unforeseen circumstances, we have had to delay this event until autumn 2021.

The USA’s failure to develop and deploy COVID-19 diagnostics in the early days of the COVID-outbreak casts in sharp relief the fragile regulatory balance between quality assurance and crisis response.  Using the FDA’s Emergency Use Authorization as prompt, this webinar considers the oblique set of trade-offs— between scientific rigour and a public good, humanitarian commitments and national primacy, resource mobilisation and market demand—R&D for medical emergencies entails.